PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study

Shao‐Liang Chen, Lijun Liu, Xiangqi Wu et al.|American Heart Journal|2024

Cited by 5